The Nodify XL2® Blood-based Lung Nodule Test: Results and Subgroup Analyses from the ORACLE Clinical Utility Study

October 17, 2022 from 10:15 am 11:00 am CDT

Supported By: Biodesix

Program Description

The ORACLE study was designed to develop real-world clinical utility data for the Nodify XL2 test. In this presentation, Dr. Jonathan Kurman, MD, MBA will review preliminary results of the primary endpoint, reduction in invasive procedures on patients with benign lung nodules, as well as subgroup analyses demonstrating the performance of the test in screen-detected versus incidental nodules and performance of the test by nodule size.

Dr. Kurman is the Director of Interventional Pulmonology and Assistant Professor of Medicine at the Medical College of Wisconsin, an early adopter of Nodify® testing, and an investigator in the ORACLE study. In addition to reviewing data from ORACLE, Dr. Kurman will discuss the impact that Nodify testing has on his practice through case studies and test results from over 100 patients with indeterminate lung nodules.

Monday, October 17, 2022 | 10:15 -11:00am CT
Presented by Dr. Jonathan Kurman, MD
Learning Theater 4

This is a non-CME event and does not qualify for CME or CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2022 conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST.


Jonathan Kurman, MD, MBA
Medical College of Wisconsin
Milwaukee, WI


Biodesix at the CHEST Annual Meeting